BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 34556401)

  • 1. Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab.
    LeClair JN; Merl MY; Cohenuram M; Luon D
    Clin Lung Cancer; 2022 Jan; 23(1):34-42. PubMed ID: 34556401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.
    Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Tamiya A; Iwasawa S; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Hirano K; Kokubo M; Yamamoto N
    Invest New Drugs; 2021 Jun; 39(3):853-859. PubMed ID: 33405089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis.
    Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Taniguchi Y; Hino A; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Matsumoto H; Kokubo M; Yamamoto N
    Lung Cancer; 2022 Sep; 171():3-8. PubMed ID: 35863254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
    Gómez Rueda A; Taus Á; Álvarez Álvarez R; Bernabé-Caro R; Chara L; López-Brea M; Vilà L; Sala González MÁ; Del Barrio Díaz Aldagalán A; Esteban Herrera B; López Castro R; Álvarez Cabellos R; Doménech M; Falagan S; Moreno Vega A; Aguado C; Barba A; Delgado Ureña MT; Isla D; Bellido Hernández L; Fírvida Pérez JL; Juan-Vidal Ó; Massutí B; Mielgo-Rubio X; Ortega AL; Catot S; Dómine M; Escoín-Pérez C; García Navalón F; Gil-Bazo I; Muñoz S; Rodríguez-Abreu D; Villatoro Roldán RM; Alonso-Jáudenes Curbera G; León-Mateos L; Padilla A; Paredes Lario A; Sánchez-Torres JM; Garrido P;
    Clin Transl Oncol; 2024 Jul; 26(7):1779-1789. PubMed ID: 38512450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.
    Naidoo J; Vansteenkiste JF; Faivre-Finn C; Özgüroğlu M; Murakami S; Hui R; Quantin X; Broadhurst H; Newton M; Thiyagarajah P; Antonia SJ
    Lung Cancer; 2022 Apr; 166():84-93. PubMed ID: 35245844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study.
    Desilets A; Blanc-Durand F; Lau S; Hakozaki T; Kitadai R; Malo J; Belkaid W; Richard C; Messaoudene M; Cvetkovic L; Kazandjian S; Tehfe M; Florescu M; Jao K; Daaboul N; Owen S; Shieh B; Agulnik J; Cohen V; Charbonneau C; Marcoux N; Blais N; Leighl NB; Bradbury PA; Liu G; Shepherd FA; Bahig H; Routy B; Sacher A; Elkrief A
    Eur J Cancer; 2021 Jan; 142():83-91. PubMed ID: 33242835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
    Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
    Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer.
    Smesseim I; Mets OM; Daniels JMA; Bahce I; Senan S
    Radiother Oncol; 2024 May; 194():110147. PubMed ID: 38341099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review.
    Zhang T; Xu K; Bi N; Zhang L; Jiang W; Liang J; Deng L; Wang X; Wang J; Wang J; Wang L
    Thorac Cancer; 2020 Oct; 11(10):2916-2923. PubMed ID: 32833338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
    Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
    Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis.
    Wang Y; Zhang T; Huang Y; Li W; Zhao J; Yang Y; Li C; Wang L; Bi N
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1154-1164. PubMed ID: 34963558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
    Jung HA; Noh JM; Sun JM; Lee SH; Ahn JS; Ahn MJ; Pyo H; Ahn YC; Park K
    Lung Cancer; 2020 Aug; 146():23-29. PubMed ID: 32505077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study.
    A K; H S; W H; As F; P WP; A R
    Cancer Treat Res Commun; 2021; 29():100496. PubMed ID: 34864586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON).
    Saito G; Oya Y; Taniguchi Y; Kawachi H; Daichi F; Matsumoto H; Iwasawa S; Suzuki H; Niitsu T; Miyauchi E; Yokoi T; Yokoyama T; Uenami T; Sakata Y; Arai D; Okada A; Nagata K; Teraoka S; Kokubo M
    Lung Cancer; 2021 Nov; 161():86-93. PubMed ID: 34543942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
    Girard N; Bar J; Garrido P; Garassino MC; McDonald F; Mornex F; Filippi AR; Smit HJM; Peters S; Field JK; Christoph DC; Sibille A; Fietkau R; Haakensen VD; Chouaid C; Markman B; Hiltermann TJN; Taus A; Sawyer W; Allen A; Chander P; Licour M; Solomon B
    J Thorac Oncol; 2023 Feb; 18(2):181-193. PubMed ID: 36307040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events.
    Miura Y; Mouri A; Kaira K; Yamaguchi O; Shiono A; Hashimoto K; Nishihara F; Shinomiya S; Akagami T; Murayama Y; Abe T; Noda SE; Kato S; Kobayashi K; Kagamu H
    Thorac Cancer; 2020 May; 11(5):1280-1287. PubMed ID: 32160383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
    Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
    Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
    Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
    Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.